15 December 2022: Calypso Biotech announces first patient with Eosinophilic Esophagitis dosed in anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 Phase 1a/b Trial, and animal proof of concept data in Atopic Dermatitis.
Posted at h
in Press release